Copyright
©The Author(s) 2023.
World J Clin Cases. Dec 16, 2023; 11(35): 8330-8342
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8330
Published online Dec 16, 2023. doi: 10.12998/wjcc.v11.i35.8330
Table 1 Characteristics of the included studies
| Included study | Year | Sample size | Mean age | Female (%) | Treatment regimen | Control group | Mean follow up duration (wk) | Patients |
| VITALITY-HFpEF | 2020 | 525 | 72.5 | 46.7 | 2.5-10 mg, QD | Placebo | 24 | EF ≥ 45%, HFpEF |
| SOCRATES-PRESERVED | 2017 | 161 | 73 | 46.0 | 2.5-10 mg, QD | Placebo | 12 | EF ≥ 45%, HFpEF |
| SOCRATES-REDUCED | 2015 | 183 | 68 | 18.0 | 2.5-10 mg, QD | Placebo | 12 | EF < 45%, HFrEF |
| VICTORIA | 2020 | 5050 | 67.3 | 23.9 | 2.5-10 mg, QD | Placebo | 43 | EF < 45%, HFrEF |
- Citation: Yang H, Luo C, Lan WQ, Tang YH. Vericiguat treatment of heart failure: A systematic review and meta-analysis. World J Clin Cases 2023; 11(35): 8330-8342
- URL: https://www.wjgnet.com/2307-8960/full/v11/i35/8330.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v11.i35.8330